Background: Systemic mastocytosis (SM) is a rare disease characterized by neoplastic mast cell (MC) infiltration of extracutaneous tissues. Nonadvanced SM (NonAdvSM) is associated with debilitating symptoms which may significantly reduce health-related quality of life (HRQoL).

In up to 95% of patients (pts), SM is driven by the somatic KIT c.2447 A>T (p.D816V) missense mutation. Bezuclastinib (bezu; CGT9486) is an oral, potent, small molecule, selective type 1 tyrosine kinase inhibitor (TKI) with activity against KIT D816V. Results from Part 1 of the 3-part Summit trial demonstrated that bezu is well-tolerated and is associated with encouraging clinical activity, including both reduced MC burden and improvement in symptoms over a 12-week (wk) period vs placebo (PBO). Based on safety, PK, biomarker, and efficacy results, a dose of 100mg QD bezu (optimized formulation) was selected for Summit Part 2.

Trial Design and Methods: Summit (NCT05186753) is a multi-center, Phase 2, double-blind, PBO-controlled RCT of bezu in pts with NonAdvSM who have inadequate control of symptoms despite treatment with best supportive care (BSC).

A novel pt-reported outcome measure, the Mastocytosis Symptom Severity Daily Diary (MS2D2), was designed to assess disease-specific symptom severity in NonAdvSM pts. Eleven symptoms are included in the MS2D2 Total Symptom Score (TSS). Summit Part 1a randomized pts 1:1:1 to PBO, 100mg, or 200mg, original formulation while Part 1b randomized 1:1:1 to PBO, 100mg, or 150mg, optimized formulation. Pts completing Part 1 of the Summit trial were allowed to receive bezu in the open-label extension (OLE) Part 3 of the trial.

Results: As Part 2 will evaluate safety and efficacy of 100 mg bezu at 24 wks, this abstract reports on pts treated with both bezu formulations at 100mg in Parts 1a or 1b, which had similar PK exposures. The presentation will focus on 24-wk outcomes in pts receiving the selected 100 mg bezu dose and participating in the OLE.

In Summit Part 1, 19 pts received PBO and 18 received 100 mg bezu for 12 wks. At baseline (BL), the symptoms identified as most severe were within the skin and fatigue domains. At BL, pts were managing their symptoms of NonAdvSM with 2 (43%), 3 (24%), or ≥4 (32%) BSC medications. At the 12-wk assessment in Part 1 (datacut 18Dec2023), the safety and tolerability profile was encouraging, with the majority of TEAEs low grade and reversible without dose modification. The most common TEAEs (>10% in 100 mg bezu) included hair color changes, nausea, diarrhea, peripheral edema, GERD, taste disorder, and neutropenia. There were no reported bleeding or cognitive impairment events. Of 37 pts randomized to PBO or 100 mg QD bezu, 36 (97%) received bezu in the OLE; one pt randomized to the 100 mg original formulation dose reduced and subsequently discontinued due to TEAE of ALT increase. All 19 PBO pts (100%) crossed over to receive bezu in the OLE; of these, 9 were randomized to the 100mg QD bezu dose. Reduction in MC burden was robust among those treated with 100mg bezu - 94.4%, 100%, and 92.3% of pts had at least a 50% reduction in basal serum tryptase, KIT p.D816V variant allele frequency, and bone marrow MCs, respectively. Pts treated with 100 mg bezu had reduction in MS2D2 TSS by 49.1% vs 21.1% with PBO. On a 0-10 scale, the most severe MS2D2 symptom mean change from BL was -3.03 from a BL mean of 7.6 with bezu vs -1.04 from a BL mean of 7.7 with PBO. Individual symptoms of the MS2D2 TSS, as well as others not in the TSS including diarrhea and brain fog, improved more with bezu than with PBO; mean change from BL ranged from -1.66 to -2.69 with bezu vs. a range of -0.52 to -1.58 with PBO. LS mean change from BL in quality of life (Mastocytosis (MC)-QoL, a disease-specific measure) was -22.05 in pts treated with 100mg bezu versus -10.71 in pts treated with PBO. Objective measurements of skin lesions, including centrally adjudicated longitudinal assessments of skin photography, also significantly reduced on bezu.

Conclusions: In Part 1 (12 wk assessment), treatment with 100mg bezu resulted in favorable safety and tolerability, significant and deep reductions across all markers of MC burden, and clinically meaningful reduction in all individual MS2D2 TSS symptoms and across domains. The presentation will report on durability and safety/tolerability data beyond 12 wks for those pts randomized to 100 mg in Part 1 and pts who crossed over from PBO in Part 1 to 100mg in Part 3. Summit Part 2 is actively enrolling.

Disclosures

Rein:DAVA Oncology: Other: Speaker, conference participant; Morphpsys: Consultancy; Incyte: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Novartis: Consultancy, Honoraria, Other: Site Principal Investigator for clinical trial, Research Funding; Sumitomo Dainippon Pharma Oncology: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Cogent Biosciences: Other: Site Principal Investigator for clinical trial, Research Funding; Protagonist: Other: Site Principal Investigator for clinical trial, Research Funding; Geron: Other: Site Principal Investigator for clinical trial, Research Funding; Blueprints Medicine: Other: Site Principal Investigator for clinical trial, Research Funding; Merck: Other: Site Principal Investigator for clinical trial, Research Funding; PharmaEssentia: Other: Site Principal Investigator for clinical trial, Research Funding; Karyopharm: Other: Site Principal Investigator for clinical trial, Research Funding; Telios Pharma: Research Funding; Silence Therapeutics: Research Funding; Sobi: Consultancy; Abbvie: Consultancy. DeAngelo:Incyte: Consultancy; Jazz: Consultancy; Kite: Consultancy; Novartis: Consultancy, Research Funding; Pfizer: Consultancy; Servier: Consultancy, Honoraria, Research Funding; Takeda: Consultancy; Bristol-Meyers Squibb: Honoraria; Abvie: Research Funding; Glycomimetics: Research Funding; Daiichi-Sankyo: Other: DSMB; Fibrogen: Other: DSMB; MT Sinai MPN Consortium: Other: DSMB; Gilead: Consultancy; Curis: Consultancy; Blueprint: Consultancy, Research Funding; Autolos: Consultancy; Amgen: Consultancy, Honoraria. Oh:Kartos Therapeutics: Consultancy; CTI BioPharma: Consultancy; Celgene/Bristol Myers Squibb: Consultancy; Disc Medicine: Consultancy; Blueprint Medicines: Consultancy; PharmaEssentia: Consultancy; Constellation: Consultancy; Geron: Consultancy; AbbVie: Consultancy; Sierra Oncology: Consultancy; Incyte: Consultancy; Novartis: Consultancy. Cridtina:AS Science: Consultancy; BluePrint: Consultancy. Ustun:Blueprint: Honoraria, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau. Boggs:Blueprint: Consultancy. Hunter:GSK: Consultancy, Honoraria; PharmaEssentia: Consultancy, Honoraria; Blueprint Medicines: Consultancy, Honoraria, Research Funding; Sobi​ (formerly CTI biopharma): Consultancy, Honoraria; Incyte: Consultancy, Honoraria, Research Funding; Cogent Biosciences: Research Funding; Ascentage Pharma: Research Funding; Syntrix Biosystems: Research Funding; Novartis: Research Funding; PharmaEssentia: Research Funding. Akin:Cogent: Consultancy, Research Funding; BluePrint: Consultancy, Research Funding; Telios: Consultancy, Research Funding; Novartis: Consultancy; Up to Date: Patents & Royalties. Kirshenbaum:Allervie Health: Current Employment, Membership on an entity's Board of Directors or advisory committees, Research Funding. Castells:Daiichi Sankyo: Consultancy; Cogent Biosciences: Research Funding; BluePrint: Research Funding. George:Blueprint Medicines Corporation: Consultancy; Cogent Biosciences: Consultancy; Beckman Coulter: Consultancy; Celgene/BMS: Consultancy; Incyte: Consultancy. Patel:BMS: Consultancy. Sun:Cogent: Current Employment, Current equity holder in publicly-traded company. Shah:Cogent: Current Employment, Current equity holder in publicly-traded company. Zhang:Cogent: Current Employment, Current equity holder in publicly-traded company. Pilla:Cogent: Current Employment, Current equity holder in publicly-traded company. Singh:Cogent: Current Employment, Current equity holder in publicly-traded company. Carden:Cogent: Current Employment, Current equity holder in publicly-traded company. Siebenhaar:Allakos: Research Funding; BluePrint: Honoraria, Research Funding, Speakers Bureau; Celldex: Research Funding; Cogent: Consultancy, Honoraria, Research Funding; Granular: Honoraria, Research Funding, Speakers Bureau; Invea: Honoraria, Research Funding, Speakers Bureau; Telios: Research Funding; ThirdHarmonicBio: Research Funding; UCB: Research Funding; Noucor: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Sanofi/Regeneron: Honoraria, Speakers Bureau. Bose:Blueprint: Honoraria, Research Funding; CTI Biopharma Corp: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Kartos: Honoraria, Research Funding; Ionis Pharmaceuticals: Research Funding; Incyte: Honoraria, Research Funding; Disc Medicine: Research Funding; Cogent: Honoraria, Research Funding; AbbVie: Honoraria; GSK: Honoraria; Astellas: Research Funding; Karyopharm: Honoraria; MorphSys: Honoraria, Research Funding; PharmaEssentia: Honoraria; Novartis: Honoraria; Telios: Research Funding; Pfizer: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding.

This content is only available as a PDF.
2024
Sign in via your Institution